Department of Computer Science, City University of Hong Kong Shenzhen Research Institute, Shenzhen, China.
BGI-Shenzhen, Shenzhen, China.
Front Immunol. 2022 Jul 28;13:848113. doi: 10.3389/fimmu.2022.848113. eCollection 2022.
Cancer driven by somatic mutations may express neoantigens that can trigger T-cell immune responses. Since T-cell receptor (TCR) repertoires play critical roles in anti-tumor immune responses for oncology, next-generation sequencing (NGS) was used to profile the hypervariable complementarity-determining region 3 (CDR3) of the TCR-beta chain in peripheral blood samples from 68 gastric cancer patients and 49 healthy controls. We found that most hyper-expanded CDR3 are individual-specific, and the gene usage of TRBV3-1 is more frequent in the tumor group regardless of tumor stage than in the healthy control group. We identified 374 hyper-expanded tumor-specific CDR3, which may play a vital role in anti-tumor immune responses. The patients with stage IV gastric cancer have higher EBV-specific CDR3 abundance than the control. In conclusion, analysis of the peripheral blood TCR repertoires may provide the biomarker for gastric cancer prognosis and guide future immunotherapy.
由体细胞突变驱动的癌症可能表达新抗原,这些抗原可以触发 T 细胞免疫反应。由于 T 细胞受体 (TCR) 库在肿瘤学的抗肿瘤免疫反应中起着关键作用,因此使用下一代测序 (NGS) 来分析 68 名胃癌患者和 49 名健康对照者外周血样本中 TCR-β 链的高变互补决定区 3 (CDR3)。我们发现,大多数超扩展的 CDR3 是个体特异性的,并且无论肿瘤分期如何,TRBV3-1 的基因使用在肿瘤组中比在健康对照组中更为频繁。我们鉴定了 374 个超扩展的肿瘤特异性 CDR3,它们可能在抗肿瘤免疫反应中发挥重要作用。IV 期胃癌患者的 EBV 特异性 CDR3 丰度高于对照组。总之,外周血 TCR 库分析可能为胃癌预后提供生物标志物,并指导未来的免疫治疗。